Code intelligence

FDA-NDA016694 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA016694.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: DEXTROSE (DEXTROSE MONOHYDRATE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA016694 · Multi-specialty

Critical

The new injectable formulation of Dextrose Monohydrate may receive a specific J-code assignment for billing under Medicare Part B. Since it is an injectable drug, it might also qualify for pass-throug

View alert